The global market for paronychia treatment is one of the steady growing markets. Paronychia usually happens when the skin around an individual's nail is irritated or harmed. Paronychia is a soft tissue infection of the skin around the fingernails and toenails. Bacteria which cause this type of infection are known as Candida. The infection begins as cellulitis but may progress to a definite abscess.
Companies are continuously inventing new products to capture the market globally. Thus, major players invest more in research and development activity, in order to lead the global market. Market players are focusing more on collaboration and acquisition in order to develop the product portfolio, which help them to lead the market and capture maximum share. Market players are continuously working to minimize the gap between demand and supply of quality treatment in order to maximize profit.
The global paronychia treatment market is expected to grow at a CAGR of 11.7% during the forecast period 2017-2023.
Segmentations
The global paronychia treatment market is segmented on the basis of type, application, and end user.
On the basis of the type, it is segmented into acute paronychia, chronic paronychia, candidal paronychia, pyogenic paronychia, and others.
On the basis of the application, it is segmented into mupirocin ointment, fusidic acid ointment, gentamicin ointment, dicloxacillin and others.
On the basis of the end user, it is segmented into hospitals & clinics, dermatology center, and others.
Key Players
Some of the key players in this market are GlaxoSmithKline plc (U.K), Glenmark Generics Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly Company (U.S.), Jonakayem Pharma Formulation Pvt. Ltd. (India), Fougera Pharmaceuticals Inc. (U.S.), Taro Pharmaceutical Industries Ltd. (U.S.), Perrigo New York, Inc. (U.S.) and others.
Request Customization
Get a Sample
Get a Sample
Request Customization